Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Open in API
Filings indexed 2,379 across all filing types
Latest filing 2025-02-14 Director's Dealing
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-02-14 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Vertex Pharmaceuticals Incorporated. It is a registration statement under the Securities Act of 1933 used for registering securities to be offered to the public. The text includes details about the securities to be offered, the registration process, and legal disclaimers. It is not a financial report, earnings release, management discussion, or any other type of report listed in the filing definitions. Instead, it is a capital markets filing related to securities offerings and fundraising activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification of the form and its purpose.
2025-02-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-13 English
10-K
Annual Report FY 2024
2025-02-13 English
FORM 4
Director's Dealing
2025-02-12 English
FORM 4
Director's Dealing
2025-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.